15.74

3.55% -0.58

After Hours: 15.74

Zymeworks Inc. (ZYME)

Overview News Price History Option Chain Discussions Forecast

Zymeworks Inc. stock is traded at $15.74, with a volume of 336.89K. It is down -3.55% in the last 24 hours and up +20.89% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Previous Close:

$16.32

Open:

$16.37

24h Volume:

336.89K

Relative Volume:

0.72

Market Cap:

$1.18B

Revenue:

$62.71M

Net Income/Loss:

$-112.51M

P/E Ratio:

-10.42

EPS:

-1.51

Net Cash Flow:

$-96.01M

1W Performance:

+4.58%

1M Performance:

+20.89%

6M Performance:

+28.18%

1Y Performance:

+29.23%

1-Day Range:

$15.73

$16.37

1-Week Range:

$14.69

$16.37

52-Week Range:

$9.03

$17.70

Zymeworks Inc. Stock (ZYME) Company Profile

Name

Zymeworks Inc.

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

604-678-1388

Address

1385 West 8th Avenue, Suite 540, Vancouver, BC

Employee

170

Twitter

@ZymeworksInc

Next Earnings Date

2024-10-31

Latest SEC Filings

ZYME's Discussions on Twitter

Compare ZYME with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZYME Zymeworks Inc.	15.74	1.15B	62.71M	-112.51M	-96.01M	-1.51
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-20-25	Initiated	TD Cowen	Buy
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-21-23	Resumed	Wells Fargo	Overweight
Jan-04-23	Reiterated	H.C. Wainwright	Neutral
Dec-20-22	Upgrade	Jefferies	Hold → Buy
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-04-22	Resumed	Wells Fargo	Overweight
May-05-22	Upgrade	Guggenheim	Neutral → Buy
Mar-15-22	Initiated	Evercore ISI	Outperform
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold
Mar-31-21	Initiated	Credit Suisse	Outperform
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-08-21	Resumed	H.C. Wainwright	Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-06-20	Initiated	SVB Leerink	Outperform
Jan-10-20	Initiated	Wolfe Research	Outperform
Dec-09-19	Initiated	JP Morgan	Neutral
Nov-25-19	Initiated	H.C. Wainwright	Buy
Nov-20-19	Initiated	Guggenheim	Buy
Sep-30-19	Upgrade	Raymond James	Outperform → Strong Buy
Aug-30-19	Initiated	Stifel	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
May-11-18	Upgrade	Barclays	Underweight → Equal Weight
Mar-19-18	Initiated	Raymond James	Outperform

View All

Zymeworks Inc. Stock (ZYME) Latest News

Sep 10, 2025

Bloom Burton Weighs in on Zymeworks FY2025 Earnings - MarketBeat

Sep 10, 2025

Zymeworks Inc.'s (NASDAQ:ZYME) 25% Price Boost Is Out Of Tune With Revenues - 富途牛牛

Sep 10, 2025

Sep 09, 2025

EcoR1 Capital LLC Has $205.56 Million Stock Holdings in Zymeworks Inc. $ZYME - MarketBeat

Sep 09, 2025

Trexquant Investment LP Acquires 118,813 Shares of Zymeworks Inc. $ZYME - MarketBeat

Sep 09, 2025

Is Zymeworks Inc. likely to announce a buybackEarnings Risk Report & Low Risk High Win Rate Stock Picks - Lancaster City Council

Sep 09, 2025

Sep 08, 2025

Analysts Set Zymeworks Inc. (NYSE:ZYME) Price Target at $21.43 - MarketBeat

Sep 08, 2025

Zymeworks Inc. Chart Enters High Volatility Zone2025 Technical Overview & Community Trade Idea Sharing - beatles.ru

Sep 08, 2025

Zymeworks (NASDAQ:ZYME) Shares Gap DownHere's What Happened - MarketBeat

Sep 08, 2025

Will Zymeworks Inc. benefit from geopolitical trends2025 Pullback Review & Safe Entry Trade Signal Reports - beatles.ru

Sep 08, 2025

Sep 07, 2025

Vestal Point Capital LP Has $5.96 Million Stock Holdings in Zymeworks Inc. $ZYME - MarketBeat

Sep 07, 2025

Can Zymeworks Inc. be recession proof2025 Bull vs Bear & Verified Trade Idea Suggestions - beatles.ru

Sep 07, 2025

ADAR1 Capital Management LLC Purchases New Holdings in Zymeworks Inc. $ZYME - MarketBeat

Sep 07, 2025